A
ArsenalBio
Developing and commercializing curative immune cell therapies
About ArsenalBio
Arsenal Biosciences, Inc. is a clinical stage biotechnology startup that operates in the healthcare sector, specifically in the field of cancer treatment. The company's primary focus is on developing programmable cell therapies aimed at combating solid tumor cancers. In simpler terms, they are working on ways to reprogram cells to fight cancer more effectively.
Their business model revolves around the research, development, and eventual commercialization of these innovative cell therapies. The company's target clients are primarily patients suffering from solid tumor cancers, a group that represents a significant portion of the global cancer patient population.
Arsenal Biosciences generates revenue through the development and sale of these therapies. As a clinical stage company, much of their current work is focused on research and development, with the goal of bringing their therapies to market. Once their therapies are approved and commercialized, the company will generate income from the sale of these treatments to healthcare providers.
The company's team is composed of experts from various scientific disciplines, as well as professionals with clinical and manufacturing experience. This diverse team is united by a common purpose: to defeat cancer through the development of innovative and effective treatments.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- South San Francisco, United States
- Employees
- 181
- Open positions
- 2
- Dealroom signal
- 62.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Rumoured $1B, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Sep 2024 | $325M | $1.3B | Kleiner Perkins · Bristol-Myers Squibb · Westlake Village BioPartners · Byers Capital | ↗ |
| SERIES BOther financing | Sep 2022 | $220M | $880M | Bristol-Myers Squibb · Emerson Collective · Euclidean Capital · Sixth Street Growth | ↗ |
Growth signals
Latest recorded traffic for ArsenalBio is 3.1K monthly website visits, down 26.2% over the last three months. ArsenalBio's team declined 26.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A16 investors entered at this stage
University of California, Santa Cruz- ECEuclidean Capital
Parker Institute for Cancer Immunotherapy
Osage Venture Partners
Kleiner Perkins
Westlake Village BioPartners
SoftBank Vision Fund
Bristol-Myers Squibb
Emerson Collective
Sixth Street Growth
Hitachi Ventures- UCUCSF Foundation Investment Company
SoftBank
Green Sands Equity- WVWaycross Ventures
Byers Capital
Series B and later7 investors entered at this stage
Rock Springs Capital
Luma Group
Regeneron Ventures
ARCH Venture Partners
T. Rowe Price
Milky Way Investments
NVentures
Other known investors2 additional known investors
University of California, San Francisco
University of Pennsylvania
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ArsenalBio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ArsenalBio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.